Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is October 27, 2025, covering share purchases executed on October 24, 2025. The transaction was conducted through BNP Paribas SA as part of GSK's existing share buyback programme, pursuant to a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for the transaction include:
- Shares Purchased: 555,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,597.50 GBp; highest price paid was 1,638.50 GBp.
- Average Price: Volume-weighted average price paid was 1,619.90 GBp.
- Treasury Holdings: Following this purchase, GSK holds 253,747,344 ordinary shares in treasury.
- Shares in Issue: 4,061,673,442 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.25% of total voting rights.
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the announcement of the non-discretionary agreement on September 30, 2025, GSK has purchased a total of 6,282,500 ordinary shares. The purchase reported in this filing increased the total treasury share count to 253,747,344. The total number of voting rights remains 4,061,673,442.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risks are referenced in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and GSK's Q2 Results for 2025. No new specific guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since September 30, 2025 (stated as 6,282,500).
- Confirm the updated treasury share count of 253,747,344 and the resulting 6.25% voting rights attribution.
- Review the detailed schedule of purchases across trading venues (XLON, BATE, CHIX) to confirm execution prices and volumes.
- Consult GSK's Annual Report on Form 20-F for 2024 and Q2 2025 Results for detailed risk factors and financial performance data not included in this filing.